i"?Bruker collaborates with the University of Victoria-Genome British Columbia Proteomics Centre.
M2 EQUITYBITES-April 25, 2013-i" Bruker collaborates with the University of Victoria-Genome British Columbia Proteomics Centre(C)2013 M2 COMMUNICATIONS http://www.m2.com
Bruker, a manufacturer of analytical and medical instruments covering NMR, ESR, FT-IR, X-RAY spectroscopy, has collaborated with the University of Victoria-Genome British Columbia Proteomics Centre.
It was reported yesterday that the collaboration is aimed at developing and validating high-throughput assays. The assays are utilised to determine hemoglobin variants and diabetes risk, using Bruker's Matrix-Assisted Laser Desorption Ionisation (MALDI) Biotyper platform for clinical mass spectrometry and based on intellectual property developed at the UVic GBC Proteomics Centre.
The new Matrix-Assisted Laser Desorption Ionisation time-of-flight mass spectrometry based test for hbA1c and genetic hemoglobin variants is intended for use on the MALDI Biotyper platform is likely to provide specificity, accuracy, speed of analysis and cost per analysis.
((Comments on this story may be sent to email@example.com)).END.PUB430>PDApril 25, 2013>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Apr 25, 2013|
|Previous Article:||i"?BD Rx receives approval for BD Simplist Metoclopramide Injection.|
|Next Article:||i"?Merck Canada to provide USD4m to Institute for Research in Immunology and Cancer - Commercialisation of Research.|